Bristol-Myers Squibb and Harvard announce new fibrosis research collaboration
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company and the Harvard Fibrosis Network of the Harvard Stem Cell Institute today announce a research collaboration to discover and develop potential new therapies for fibrotic diseases, including fibrosis of the liver and heart. The Harvard Fibrosis Network brings together researchers across the schools and affiliated hospitals of Harvard University.
Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader
- Details
- Category: Novartis
Novartis announced today that it has entered into an agreement and plan of merger with AveXis, Inc. to acquire the US-based Nasdaq-listed clinical stage gene therapy company for USD 218 per share or a total of USD 8.7 billion in cash. The transaction was unanimously approved by the Boards of both companies.
Boehringer Ingelheim and OSE Immunotherapeutics announce global immuno-oncology partnership to develop a pioneering checkpoint inhibitor for the treatment of advanced solid tumors
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, have announced a collaboration and exclusive worldwide collaboration and license agreement to jointly develop OSE-172, a SIRP-alpha antagonist targeting myeloid lineage cells.
Combining tradition with modernity: Bayer hones its brand profile
- Details
- Category: Bayer
Dynamic, open, personal: From today forward, these attributes will be the new public face of the Bayer brand. As CEO Werner Baumann explained: "Our brand is our most important distinguishing feature. People from all over the world have been placing their trust in Bayer for more than 150 years."
Pfizer and Allogene Therapeutics enter into asset contribution agreement for Pfizer's allogeneic CAR T immuno-oncology portfolio
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) and Allogene Therapeutics, Inc. (Allogene) today announced that the two companies have entered into an asset contribution agreement for Pfizer's portfolio of assets related to allogeneic chimeric antigen receptor T cell (CAR T) therapy, an investigational immune cell therapy approach to treating cancer.
Merck partners with Medisafe to help improve medication adherence for cardiometabolic patients
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication intake and adhere to prescribed treatment regimens. In the countries of scope Merck patients will have access to a customized version of Medisafe's mobile platform that could combine reminders, motivation and support systems, targeted content, coupons and interventions in their local language.
GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Joint Venture for $13 billion (£9.2 billion). The Consumer Healthcare Joint Venture was formed as part of the three-part transaction between GSK and Novartis which was approved by shareholders in 2014.
More Pharma News ...
- Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS
- Lokelma approved in the EU for the treatment of adults with hyperkalaemia
- Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies
- FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease
- Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson's disease
- New data from landmark CVD-REAL study of patients with type-2 diabetes confirms CV benefits associated with SGLT-2 Inhibitors
- Novartis announces changes to the Executive Committee to support strategic priorities